Key Highlights

  • Shareholders voted to increase the 2021 Stock Incentive Plan by 2,000,000 shares, enhancing the pool for future equity grants.
  • The company received approval for warrant holders to purchase up to 39,618,078 shares of common stock.
  • Deloitte & Touche LLP was ratified as the independent accounting firm for the upcoming fiscal period.

Cellectar Biosciences, Inc. (NASDAQ: CLRB) shared the outcomes of its annual shareholders’ meeting, which took place on July 7, 2026. The gathering addressed several key governance and capital‑structure items, reflecting the company’s ongoing efforts to support its growing pipeline in oncology therapeutics.

Board Update

During the meeting, shareholders elected Andrew Gu and Douglas J. Swirsky to serve as Class III directors for a three‑year term. Their appointment is expected to strengthen the board’s oversight of scientific development and financial strategy, given their backgrounds in biotech investment and corporate finance.

Expansion of the Stock Incentive Plan

Investors approved an amendment to the 2021 Stock Incentive Plan, authorizing the issuance of an additional 2,000,000 shares. This increase provides Cellectar with greater flexibility to attract and retain talent through equity‑based compensation, a critical component for companies operating in the competitive biotechnology sector.

Auditor Confirmation

The audit committee’s recommendation of Deloitte & Touche LLP as the independent accounting firm for the forthcoming fiscal period was affirmed by shareholders. Continuity with a well‑known auditor supports transparent financial reporting and aligns with best practices for publicly traded life‑science companies.

Executive Compensation Advisory Vote

Shareholders cast non‑binding advisory votes on the compensation packages for the company’s named executive officers. The affirmative votes indicate general approval of the current remuneration framework, which ties a portion of executive pay to the achievement of key milestones in drug development. This permission enables the company to raise additional capital should market conditions be favorable, while also providing warrant holders with the opportunity to convert their instruments into equity.

Meeting Proceedings

Because the warrant exercise proposal secured approval, the agenda item proposing an adjournment of the meeting was rendered unnecessary and therefore was not presented. Overall, the results of the July 7 meeting illustrate Cellectar’s commitment to reinforcing its corporate governance, expanding its equity incentive tools, and maintaining strong audit oversight, all essential elements as the company advances its clinical programs and seeks to position itself for future growth in the oncology market.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.